GK Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

GK Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$385K	Sell	736 -186	-20%	-$95.2K	0.22%	89
2026 Q2	$458K	Buy	+922	New	+$409K	0.24%	108
2026 Q1	–	Sell	-732	Closed	-$332K	–	213
2025 Q4	$332K	Sell	732 -35	-5%	-$15.1K	0.22%	114
2025 Q3	$300K	Buy	767 +78	+11%	+$32.6K	0.22%	109
2025 Q2	$307K	Buy	+689	New	+$318K	0.28%	96

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

AMF Tjänstepension Stockholm, Sweden $17.2B AUM 28.3% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Montrusco Bolton Investments Montreal, Quebec, Canada $5.77B AUM 24.61% 1-Year Est. Return

Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return

Asset Management One Tokyo, Japan $40B AUM 30.45% 1-Year Est. Return

GK Wealth Management's VRTX Position: Q3 2026 in Review

GK Wealth Management reduced its Vertex Pharmaceuticals (VRTX) stake by 20% in Q3 2026, selling an estimated $95.2K and leaving 736 shares worth $385K. The position accounts for 0.22% of the portfolio, ranked #89.

GK Wealth Management first reported a position in VRTX in Q2 2025 and has held it in 5 quarters since. The position peaked at $458K in Q2 2026. 576 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

GK Wealth Management held 736 shares of Vertex Pharmaceuticals worth $385K as of Q3 2026.
GK Wealth Management sold 186 Vertex Pharmaceuticals shares in Q3 2026, an estimated $95.2K.
Vertex Pharmaceuticals made up 0.22% of GK Wealth Management's portfolio in Q3 2026, its #89 holding.
GK Wealth Management first reported a position in Vertex Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
GK Wealth Management's Vertex Pharmaceuticals position peaked at $458K in Q2 2026.
576 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on GK Wealth Management's 13F filing for Q3 2026, filed 9 Oct 2026.